Itzhak Israel - Purple Biotech Chief Executive Officer & Director
KTOV Stock | ILA 17.90 1.10 5.79% |
CEO
Mr. Itzhak Israel serves as Chief Executive Officer and Director at Kitov Pharma Ltd since October 31, 2012. Mr. Israel work experience includes the following roles Founder and Chief Executive Officer of Uneri Capital Ltd, Director at a variety of healthcare companies, Chairman of the Board at NextGen Biomed Ltd and Consultant to Capital Point Ltd. since 2012.
Age | 38 |
Tenure | 12 years |
Phone | 972 3 933 3121 |
Web | http://www.kitovpharma.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 1 records | CEO Age | ||
Anat CohenDayag | Compugen | 56 |
Management Performance
Return On Equity | -0.92 | |||
Return On Asset | -0.0915 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itzhak Israel, Chief Executive Officer & Director | ||
Steven Steinberg, Independent Director | ||
Gil BenMenachem, Vice President - Business Development | ||
Michael Schickler, Head of Clinical Operations | ||
Philip Serlin, Independent Director | ||
CPA MBA, Strategic Director | ||
Arie Weber, Independent Director | ||
Bertrand Liang, Chief Medical Officer | ||
Yisrael Gewirtz, Internal Auditor | ||
John Waymack, Chairman of the Board & Chief Medical Officer | ||
Ran Tzror, Independent Director | ||
Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer | ||
Simcha Rock, CFO, Director | ||
Eric Rowinsky, Chairman of the Board | ||
Moran SherfBlau, External Director | ||
Ido Agmon, Independent Director | ||
Gil CPA, Deputy CFO | ||
Leah Bruck, Director | ||
Isaac Israel, CEO Director | ||
Revital SternRaff, Independent Director | ||
Pinhas BarShmuel, Internal Auditor | ||
Avraham BenTzvi, General Counsel, Secretary | ||
Alain Zeitoun, External Director | ||
Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary) |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.92 | |||
Return On Asset | -0.0915 | |||
Operating Margin | (7.54) % | |||
Shares Outstanding | 172.11 M | |||
Shares Owned By Insiders | 0.12 % | |||
Shares Owned By Institutions | 1.22 % | |||
Price To Earning | (364.21) X | |||
Price To Book | 1.27 X | |||
Price To Sales | 16.36 X | |||
Revenue | 1000 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |